Kenvue Marks Independence By Extending Motrin And Tylenol Lines With Help From A Competitor

Kenvue also not standing apart from competitors concerning headwinds from foreign exchange rates, a slow start to the cough/cold season and looking ahead to FDA decision on oral phenylephrine, it reports with its third-quarter results.

• Source: Shutterstock

Kenvue Inc.’s early months as a standalone company, after Johnson & Johnson sold its controlling stake, haven’t meant it’s standing alone in the consumer health segment and isn’t working with competitors to expand its business.

Neither is Kenvue standing apart from its competitors concerning headwinds from foreign exchange rates, the firm reported 26 October with...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Earnings

More from Business